126832-82-4

Basic information

• Product Name: 1-Pyridin-4-ylmethylpiperidin-4-one
• Synonyms: 1-PYRIDIN-4-YL-METHYLPIPERIDIN-4-ONE;1-((PYRIDINE-4-YL)METHYL)PIPERIDINE-4-ONE;1-Pyridin-4-yl-methylpiperidin-4-one95%;1-PYRIDIN-4-YL-METHYLPIPERIDIN-4-ONE 95%;Zinc02563767;1-(4-PyridinylMethyl)-4-piperidone
• CAS NO: 126832-82-4
• Molecular Formula: C11H14N2O
• Molecular Weight: 190.24
• Mol File: 126832-82-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 337.466 °C at 760 mmHg
• Flash Point: 157.894 °C
• Appearance: /
• Density: 1.149 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.00±0.20(Predicted)
• CAS DataBase Reference: 1-Pyridin-4-ylmethylpiperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyridin-4-ylmethylpiperidin-4-one(126832-82-4)
• EPA Substance Registry System: 1-Pyridin-4-ylmethylpiperidin-4-one(126832-82-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 126832-82-4(Hazardous Substances Data)

Usage

Uses

1-(Pyridin-4-ylmethyl)piperidin-4-one is a useful research chemical.

InChI:InChI=1/C11H14N2O/c14-11-3-7-13(8-4-11)9-10-1-5-12-6-2-10/h1-2,5-6H,3-4,7-9H2

Upstream product

• 41979-39-9 4-piperidone hydrochloride 
• 1822-51-1 4-picolylchloride hydrochloride 
• 41661-47-6 piperidin-4-one 

Relevant articles and documents

Design, synthesis and biological activities of piperidine-spirooxadiazole derivatives as α7 nicotinic receptor antagonists

α: 7 nicotinic acetylcholine receptors (nAChRs) expressed in the nervous and immune systems have been suggested to play important roles in the control of inflammation. However, the lack of antagonist tools specifically inhibiting α7 nAChR impedes the validation of the channel as therapeutic target. To discover a selective α7 antagonist, we started a pharmacophore-based virtual screening and identified a piperidine-spirooxadiazole derivative T761–0184 that acts as a α7 antagonist. A series of novel piperidine-spirooxadiazole derivatives were subsequently synthesized and evaluated using two-electrode voltage clamp (TEVC) assay in Xenopus oocytes. Lead compounds from two series inhibited α7 with their IC50 values ranging from 3.3 μM to 13.7 μM. Compound B10 exhibited α7 selectivity over other α4β2 and α3β4 nAChR subtypes. The analysis of structure-activity relationship (SAR) provides valuable insights for further development of selective α7 nAChR antagonists.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound by the following general formula (1): wherein, R1, R2and R3each independently represent a hydrogen atom or an alkoxy group W1and W2each independently represent N or CH; X represents O, NR4, CONR4or NR4CO; R4represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2and R3each independently represent a hydrogen atom or an alkoxy group; W1an W2each independently represent N or